Onyx (ONXX) Delays NDA for Carfilzomib Due to Recent CMC Meeting

October 7, 2010 4:59 PM EDT Send to a Friend
Onyx (Nasdaq: ONXX) delaying its NDA for carfilzomib based on a recent CMC meeting. The FDA requested added CMC information.

Onyx expects to file an NDA for accelerated approval as early as mid-2011.

The company has said the clinical profile of carfilzomib has not changed.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Hot List

Add Your Comment